ALS trial research

The highway towards a cure

TRICALS is the largest European research initiative to find a cure for ALS to date. 48 top research centres in 16 countries have joined hands with patient organisations and fundraisers to reach our one goal: find effective treatments for ALS.

Find out more about the highway 
towards a cure in this video.
Creating a world without ALS, together

The very best experts from top research centres around the globe have teamed up with patient organisations, fundraisers and pharma companies in a unique international collaboration to find a cure for ALS

Learn more
The best research centers

Top research centres in 16 countries have joined hands with patients’ organisations and fundraisers to reach our one goal: find a treatment for ALS within 5 years

Make a difference

Join us in our mission to make ALS treatable. Support one of our running campaigns or start your own. Together we will create a world without ALS.

Become a fundraiser

Danny - patient

The perfect platform to unite

“I believe TRICALS will be the perfect platform to unite patients, pharma and researchers that want to contribute to get rid of this disease”

Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more
Do you have any questions?

For general inquiries please contact us by using the contact form. For questions about clinical trials, please contact a TRICALS center close to you.